AI
ANIP icon

Atom Investors’s ANI Pharmaceuticals ANIP Stock Holding History

Atom Investors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,693
Closed -$306K – 429
2023
Q2 		$306K Buy
+5,693
New +$252K 0.12% 185

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Atom Investors's ANIP Position: Q3 2023 in Review

Atom Investors sold out of ANI Pharmaceuticals (ANIP) in Q3 2023, closing a stake of 5,693 shares — an estimated $306K sold.

Atom Investors first reported a position in ANIP in Q2 2023 and held it in 1 quarter. The position peaked at $306K in Q2 2023. 185 funds tracked by Wall St. Rank hold ANIP as of Q3 2023.

  • Atom Investors reported no remaining ANI Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Atom Investors sold 5,693 ANI Pharmaceuticals shares in Q3 2023, an estimated $306K.
  • Atom Investors first reported a position in ANI Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Atom Investors's ANI Pharmaceuticals position peaked at $306K in Q2 2023.
  • 185 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2023.

Based on Atom Investors's 13F filing for Q3 2023, filed 14 Nov 2023.